Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2019

Open Access 01-12-2019 | Insulins | Research

Impact of type 2 diabetes treated with non-insulin medication and number of diabetes-coexisting diseases on EQ-5D-5 L index scores in the Finnish population

Authors: Kari Jalkanen, Emma Aarnio, Piia Lavikainen, Hanna-Mari Jauhonen, Hannes Enlund, Janne Martikainen

Published in: Health and Quality of Life Outcomes | Issue 1/2019

Login to get access

Abstract

Background

Type 2 diabetes (T2D) causes significant health and economic burden. In addition to comorbidities there are also coexisting diseases linked to obesity, lifestyle and T2D. The aim of this study was to examine the effect of T2D and T2D-coexisting diseases on health-related quality of life (HRQoL) in the Finnish population and whether it is T2D or the coexisting diseases that have the largest impact on HRQoL.

Methods

The study was based on a national cross-sectional population survey (n = 5305). Respondents’ HRQoL was measured using the EQ-5D-5 L instrument. Our study included diabetic respondents treated with non-insulin medications (NI-T2D) with or without insulin and non-diabetic respondents, whereas diabetic respondents not taking any anti-diabetic medications or treated with insulin alone were excluded. A crosswalk algorithm was used to convert EQ-5D-5 L index scores into EQ-5D-3 L index scores as a sensitivity analysis. A two-part model was used to examine the association between T2D and coexisting diseases and HRQoL.

Results

The unadjusted mean (SD) EQ-5D-5 L index scores for non-diabetics (n = 4856) was 0.90 (0.13) and 0.85 (0.16) for respondents with NI-T2D (n = 449). With adjustment for demographic factors, the difference in EQ-5D-5 L index scores was 0.036 (95% CI 0.023–0.050). After adjusting for the number of coexisting diseases, the EQ-5D-5 L index scores among respondents with NI-T2D and three or more coexisting diseases were lower when compared to all non-diabetics but not when compared to non-diabetics with similar number of coexisting diseases. The number of T2D-coexisting diseases had a larger effect on EQ-5D-5 L index scores in younger age groups (20 and 40 years old).

Conclusions

Lower EQ-5D-5 L index score is associated with NI-T2D when compared to non-diabetic respondents. When compared to non-diabetics, the disutility associated with NI-T2D increases as more coexisting diseases appear. The disutility effect of coexisting diseases was equally large in non-diabetics and respondents with NI-T2D. Thus, public health interventions targeting the prevention of both T2D and its coexisting diseases have potential to have significant benefits also in terms of HRQoL.
Appendix
Available only for authorised users
Literature
1.
Forouzanfar MH, Afshin A, Alexander LT, Biryukov S, Brauer M, Cercy K, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1659–724.CrossRef
2.
3.
Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes. Ann Intern Med. 2014;122:481–6.CrossRef
4.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with obesity. J Am Med Assoc. 2013;282:1523–9.CrossRef
5.
6.
7.
8.
Koski S, Kurkela O, Ilanne-Parikka P, Rissanen P. Diabeteksen kustannukset Suomessa 2002–2011 (The Cost of diabetes in Finland 2002–2011) (in Finnish). 2018;2002–5.
9.
The WHOQOL Group. The Workd health organization quality of life assessment (WHO-QOL): Developlment and general psychometric qualities. Soc Sci Med. 1998;46:1569–85.CrossRef
10.
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001.
11.
Adriaanse MC, Drewes HW, van der Heide I, Struijs JN, Baan CA. The impact of comorbid chronic conditions on quality of life in type 2 diabetes patients. Qual Life Res Springer International Publishing; 2016;25:175–182.CrossRef
12.
Takahara M, Katakami N, Shiraiwa T, Abe K, Ayame H, Ishimaru Y, et al. Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L. Acta Diabetol Springer Milan. 2018;56:309–19.CrossRef
13.
Sayah F. Al, Qiu W, Xie F, Johnson JA. Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes. Qual life res. Springer International Publishing. 2017;26:2057–66.
14.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef
15.
Pan CW, Sun HP, Zhou HJ, Ma Q, Xu Y, Luo N, et al. Valuing health-related quality of life in type 2 diabetes patients in China. Med Decis Mak. 2016;36:234–41.CrossRef
16.
17.
Hitt HC, McMillen RC, Thornton-Neaves T, Koch K, Cosby AG. Comorbidity of obesity and pain in a general population: results from the southern pain prevalence study. J Pain. 2007;8:430–6.CrossRef
18.
Jacobsen AR, Eriksen F, Thorup L, Skødeberg LB, Holm JPY, Hansen KW. Newly diagnosed obstructive sleep apnoea and type 2 diabetes mellitus. Dan Med J. 2017;64:3–7.
19.
Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Heal Elsevier. 2016;19:1002–8.CrossRef
20.
Cardiovascular disease and risk management: standards of medical care in diabetes 2018. Diabetes care. 2018. p. S86–104.
21.
Järvisilta K, Niemelä M, Aaltonen K, Merikoski MEH. Fimea medicines barometer 2015. Description of data and data collection of population surveys; 2018.
22.
Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. Diabet Med. 2011;28:395–413.CrossRef
23.
Konerding U, Elkhuizen SG, Faubel R, Forte P, Malmström T, Pavi E, et al. The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014;12:1–11.CrossRef
24.
25.
The Finnish Medicines Agency and the Social Insurance Institution of Finland. Finnish statistics on medicines. Helsinki; 2017.
26.
Brazier JE, Ratcliffe J, Tsuchiya A, Solomon J. Measuring and valuing health for economic evaluation. 2nd ed. Oxford: Oxford University Press; 2017.
27.
Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2017:1–16.
28.
Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, et al. Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets. Pharmacoeconomics Springer International Publishing. 2018:1–15.
29.
30.
Redekop WK, Koopmanschap M. A., Stolk RP, Rutten GEHM, Wolffenbuttel BHR, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458–63.CrossRef
31.
Lubetkin EI, Jia H, Franks P, Gold MR. Relationship among sociodemographic factors, clinical conditions, and health-related quality of life: examining the EQ-5D in the U.S. general population. Qual Life Res. 2005;14:2187–96.CrossRef
32.
Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas Y, Niakas D. Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res. 2009;18:87–97.CrossRef
33.
Mateo DC, Gordillo MAG, Olivares PR, Adsuar JC. Datos normativos del EQ-5D-5L en pacientes diabéticos de España. Nutr Hosp. 2015;32:1595–602.
34.
Saarni SI, Härkänen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15:1403–14.CrossRef
35.
McClure NS, Al SF, Ohinmaa A, Johnson JA. Minimally important difference of the EQ-5D-5L index score in adults with type 2 diabetes. Value Heal Elsevier Inc. 2018:1–8.
36.
Wasem J, Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, et al. Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy - an analysis of the DiaRegis registry. Cardiovasc Diabetol. 2013;12:1–8.CrossRef
37.
Grandy S, Fox KM. Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. Health Qual Life Outcomes [Internet] Health and Quality of Life Outcomes; 2012;10:1. Available from: Health and Quality of Life Outcomes.
38.
Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M. Health-related quality of life in type 2 diabetes (TARDIS-2). Value heal. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 2000;3(Suppl 1):47–51.
39.
Amer A-S, Taha A, Ahmed B, Mohammed S. Health-related quality of life in type 2 diabetic patients. Ann Saudi Med. 2008;28:352–60.CrossRef
40.
Lam MCJ, Wodchis PW. The relationship of 60 disease diagnoses and 15 conditions to preference- based health- related quality of life in Ontario hospital- based long- term care residents. Med Care. 2010;48:380–7.CrossRef
41.
Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230–6.CrossRef
42.
Toivanen AT, Heliövaara M, Impivaara O, Arokoski JPA, Knekt P, Lauren H, et al. Obesity, physically demanding work and traumatic knee injury are major risk factors for knee osteoarthritis-a population-based study with a follow-up of 22 years. Rheumatology. 2010;49:308–14.CrossRef
43.
Boylan MR, Khalili H, Huang ESCA. Measures of adiposity are associated with increased risk of peptic ulcer. Clin Gastroenterol Hepatol. 2014;12:1688–94.CrossRef
44.
Pihlajamäki J, Männikkö R, Tilles-Tirkkonen T, Karhunen L, Kolehmainen M, Schwab U, et al. Digitally supported program for type 2 diabetes risk identification and risk reduction in real-world setting: protocol for the StopDia model and randomized controlled trial. BMC Public Health. 2019:1–13.
45.
Devlin N, Brazier J, Pickard AS, Stolk E. 3L, 5L, what the L? A NICE conundrum. Pharmacoeconomics. 2018;36:637–40 Springer International Publishing.CrossRef
46.
Round J. Once bitten twice shy: thinking carefully before adopting the EQ-5D-5L. Pharmacoeconomics. Springer International Publishing; 2018;18–20.
47.
48.
AJ C, JP N. Handbook of Health Economics. Handb heal econ. Amsterdam: Elsevier. p. 265–344.
49.
Busschbach J, Weijnen T, Nieuwenhuizen Oppe S, Badia X, Dolan P, Greiner W, Kind P, Krabbe P, Ohinmaa A, Roset M, Sintonen H, Tsuchiya A, Williams A, Yfantopoulos JDCFA. Comparison of EQ-5D time trade-off values obtained in Germany, United Kingdom, Spain. In: Brooks RG, Rabin FDC, editors. Meas Valuat heal status using EQ-5D a Eur Perspect. Boston: Kluwer Academic Publishers; 2003. p. 143–65.CrossRef
50.
Karlsson JA, Nilsson JÅ, Neovius M, Kristensen LE, Gülfe A, Saxne T, et al. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients. Ann Rheum Dis. 2011;70:2163–6.CrossRef
Metadata
Title
Impact of type 2 diabetes treated with non-insulin medication and number of diabetes-coexisting diseases on EQ-5D-5 L index scores in the Finnish population
Authors
Kari Jalkanen
Emma Aarnio
Piia Lavikainen
Hanna-Mari Jauhonen
Hannes Enlund
Janne Martikainen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2019
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-019-1187-9

Other articles of this Issue 1/2019

Health and Quality of Life Outcomes 1/2019 Go to the issue

Research

Impact of missing data on bias and precision when estimating change in patient-reported outcomes from a clinical registry

Research

Development and validation of a sexual relations satisfaction scale in patients with breast cancer — “SEXSAT-Q”

Research

Inflammation and quality of life in later life: findings from the health, well-being and aging study (SABE)

Research

Associations between combined overweight and obesity, lifestyle behavioural risk and quality of life among Australian regional school children: baseline findings of the Goulburn Valley health behaviours monitoring study

Research

Assessing quality of life in people with HIV in Spain: psychometric testing of the Spanish version of WHOQOL-HIV-BREF

Research

The mediating role of sleep quality in the association between nocturia and health-related quality of life